The Renal Association seeks to involve its Corporate Members widely in all areas of the Association’s activities of mutual relevance. Contact the Secretary or the Treasurer to discuss this.
Otsuka Pharmaceutical is a global healthcare company with the corporate philosophy ‘Otsuka-people creating new products for better health worldwide.’ The Otsuka Group is comprised of 166 companies and employs approximately 44,000 people globally with products available in more than 80 countries worldwide.
Otsuka is committed to focusing its research and development on innovative products and medical devices that address unmet medical needs, particularly in our specialist areas of renal, endocrine, gastrointestinal and central nervous system disorders.
Chronic kidney disease (CKD) is a key strategic area of focus within AstraZeneca’s Cardiovascular and Metabolic Diseases (CVMD) therapy area. By leveraging our expertise in diabetes and cardiovascular disease, AstraZeneca is able to better understand the interplay of these conditions and CKD to advance our scientific leadership in the cardio-renal space.
Through novel therapies and therapy combinations that target both the complications of CKD and the underlying mechanisms of CKD progression, we are building a portfolio to prevent, treat, manage and modify this global public health issue. For more information please visit www.astrazeneca.co.uk. [AstraZeneca Document Number: GB-8259 Date of Preparation: August 2017]